Glioblastoma is the most aggressive and malignant form of glioma, a type of primary brain cancer. Surgery is often used to treat gliomas, along with radiation. However, since surgery and radiation fail to cure the disease, doctors may turn to additional radiation or chemotherapy. In early stages glioblastoma tumors often grow without symptoms and therefore can become quite large before symptoms arise. When the tumor becomes symptomatic, tumor growth is usually very rapid and is accompanied by altered brain function, and if left untreated the disease becomes lethal. Although primary treatment is often successful in temporarily stopping the progression of the tumor, glioblastomas almost always recur and become lethal.
Deciphera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, announced the presentation today of updated preliminary results from its ongoing Phase 1 clinical study of DCC-2618, the company's broad-spectrum KIT and PDGFRα inhibitor, in patients with gastrointestinal stromal tumors as a proffered paper presentation at the European Society of Medical Oncology 2018 Congress in Munich, Germany.
A new study from Helsinki University Hospital, University of Helsinki and the Finnish Cancer Registry shows that survival after glioblastoma has improved since the millennium. The improvement in survival was, however, modest in elderly patients, raising concerns whether current treatment strategies are optimal for this patient group.
A new blood test for children with brain tumors offers a safer approach than surgical biopsies and may allow doctors to measure the effectiveness of treatment even before changes are identified on scans, according to research led by UCSF Benioff Children’s Hospitals and Children’s National Health System.
A specific protein called TEAD1 is an important regulator of tumor migration in glioblastoma, the most common brain tumor in adults, and deactivating this protein may stop tumor cells from migrating away from the main tumor mass, according to research conducted at the Icahn School of Medicine at Mount Sinai and published October 1 in the journal Nature Communications.
Combating glioblastoma remains a major challenge due the complex nature of these tumors, the inability of drugs to penetrate the brain tissue, and lack of correlation between animal models and the human condition.
Zika virus infection is a dreaded one that can lead to severe brain damage in the unborn babies of mothers who get it.
Researchers at The University of Texas Medical Branch at Galveston have successfully harnessed a Zika virus vaccine under development to target and kill the brain cancer known as glioblastoma.
An international team of researchers has successfully deployed a Zika virus vaccine to target and kill human glioblastoma brain cancer stem cells, which had been transplanted into mice.
Rush University Medical Center is part of a new clinical trial testing whether an experimental vaccine can help patients' immune systems stop the spread of glioblastoma -- an aggressive form of brain cancer with veryhttps://www.rush.edu/news/press-releases/rush-testing-new-brain-cancer-vaccine few current treatment options.
Scientists with the Virginia Tech Carilion Research Institute say a gene involved in the body's circadian rhythms is a potential target for therapies to help patients with a deadly form of brain cancer known as glioblastoma.
Barrow Neurological Institute has initiated a $50 million effort, supported by the single largest research grant in the history of brain tumor research, to seek a cure for the deadliest form of brain cancer.
UC San Francisco researchers have discovered how a mutation in a gene regulator called the TERT promoter -- the third most common mutation among all human cancers and the most common mutation in the deadly brain cancer glioblastoma -- confers "immortality" on tumor cells, enabling the unchecked cell division that powers their aggressive growth.
In order to halt the growth of cancer cells, you have to know what feeds them. Researchers at the nationally recognized Kidney Cancer Program at UT Southwestern's Harold C. Simmons Comprehensive Cancer Center have developed a novel approach using glucose that may open up new opportunities for therapeutic intervention.
The latest in a series of laboratory breakthroughs could lead to a more effective way to treat the most common brain cancer in children.
Adding another inhibitor to therapies that cut off a tumor's access to blood vessels could be the key to helping those therapies overcome resistance in glioblastoma, a deadly form of brain cancer.
The death today of Sen. John McCain (R-Ariz.) sheds a new light on glioblastoma, a form of brain cancer that the American Brain Tumor Association estimated would be diagnosed in nearly 13,000 people this year.
There are many lawmakers who made their names in health care, seeking to usher through historic changes to a broken system.
Certain brain cancers are associated with low numbers of immune system T-cells circulating in the peripheral blood. Low T-cell numbers can be a side-effect of cancer treatment. But it now appears that there is more to the story of these missing T-cells.
The blood-brain barrier is a specialized network of vascular and brain cells that acts as the brain's security system, helping to safeguard the brain and regulate the flow of substances into and out of it.
Glioblastoma brain tumors can have an unusual effect on the body's immune system, often causing a dramatic drop in the number of circulating T-cells that help drive the body's defenses.